Compare CVS Health Corp (CVS) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs YieldMax NVDA Option Income Strategy ETF — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while YieldMax NVDA Option Income Strategy ETF trades at $12.78 (market cap $1.46B). The key difference: CVS Health Corp is far larger — about 77× YieldMax NVDA Option Income Strategy ETF's market cap, and CVS Health Corp pays a 3.02% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| CVS | NVDY | |
|---|---|---|
Market Cap | $112.49B | $1.46B |
Volume | 8,467,392 | 1,111,033 |
Sector | Health | Income / Options Overlay |
52-Week High | $110.60 | $17.21 |
52-Week Low | $70.08 | $11.58 |
Typical Hold Time | 83 Days | 43 Days |
Enterprise Value | $174.83B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
NVDY trades at $13.01, down 0.31% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, averaging around $0.10 per share recently, reflecting its income-focused strategy tied to NVIDIA's stock volatility. However, key valuation ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook is mixed: strong dividend yields appeal to income seekers, but structural caps on upside participation and potential NAV erosion pose long-term risks. Analyst sentiment has shifted to hold due to declining volatility in NVIDIA, suggesting cautious optimism for income but limited growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
